| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/01/2005 | US6849653 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 02/01/2005 | US6849648 Phenylene alkyne matrix metalloproteinase inhibitors |
| 02/01/2005 | US6849646 Chromenone and chromanone derivatives as integrin inhibitors |
| 02/01/2005 | US6849643 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 02/01/2005 | US6849639 Anticancer agents, antiinflamatory agents, osteoporosis, atherosclerosis |
| 02/01/2005 | US6849638 Phosphodiesterase enzyme 7b (pde7b) inhibitors; treating osteoporosis, osteopenia and asthma |
| 02/01/2005 | US6849637 Matrix metalloproteases (MMPs) inhibitors such as benzyl 4-benzyl-5-oxo-4H-(1,2,4)triazolo(4,3-a)quinazol-7-ylcarboxylate for inflammatory conditions such as rheumatoid arthritis or osteoarthritis, or cancer |
| 02/01/2005 | US6849635 Sulfonamides |
| 02/01/2005 | US6849632 Heteroaryl alkyl piperazine derivatives |
| 02/01/2005 | US6849631 Semicarbazides and their uses |
| 02/01/2005 | US6849629 Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders |
| 02/01/2005 | US6849626 Aza-amino acid derivatives (factor Xa inhibitors 15) |
| 02/01/2005 | US6849625 Use in manufacture of a medicament for use as an anti-invasive agent in containment and/or treatment of solid tumor disease |
| 02/01/2005 | US6849621 Treating: allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep |
| 02/01/2005 | US6849617 Administering Tissue factor pathway inhibitors for prophylaxis of thrombosis and cardiovascular disorders; anticoagulants |
| 02/01/2005 | US6849601 A conotoxin proteins is adrenergic blocking agents, treating disorders of urinary or cardiovascular conditions, having alpha 1-adrenoceptor antagonist activity |
| 02/01/2005 | US6849597 Administering a growth hormone secretagogue to a mammal, for preventing nerve cells degeneration or death of neurons |
| 02/01/2005 | US6849438 Isolated and purified human soluble guanylyl cyclase α1/β1 (hsgcα1/β1) |
| 02/01/2005 | US6849436 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders, gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria |
| 02/01/2005 | US6849262 Vascular coating composition |
| 02/01/2005 | US6849257 Comprises catalytic or stoichiometric lipid removal, wherein proteins and/or polypeptides (lysosoymal acid lipase) target receptors in and/or on the cell which lead to uptake into the lysosome |
| 02/01/2005 | CA2133324C Parenteral solutions containing 3-dialkylaminoethoxybenzoyl-benzofurans |
| 01/31/2005 | CA2475968A1 A coating for implantable medical devices to control drug elution from abasecoat |
| 01/27/2005 | WO2005008250A1 Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway |
| 01/27/2005 | WO2005007845A2 Transgenic cells |
| 01/27/2005 | WO2005007838A1 Cell diffrentiation inhibitor, cell culture method using the same, liquid culture medium and cultured cell line |
| 01/27/2005 | WO2005007644A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 01/27/2005 | WO2005007239A1 Use of dapsone as a neuroprotector in cerebral infarction |
| 01/27/2005 | WO2005007192A2 Cytoprotection through the use of hif hydroxylase inhibitors |
| 01/27/2005 | WO2005007173A1 Use of nitrite salts for the treatment of cardiovascular conditions |
| 01/27/2005 | WO2005007157A1 Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases |
| 01/27/2005 | WO2004087120A3 Use of quinazoline derivatives with src kinase inhibitory activity for the treatment of hypertension |
| 01/27/2005 | WO2004062553A3 Affinity screening using “one-bead-one-compound” libraries |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | US20050020832 For therapy of atherosclerosis |
| 01/27/2005 | US20050020691 Pharmaceutical preparations comprising substituted beta-aminoalcohols |
| 01/27/2005 | US20050020684 Modulators of peroxisome proliferator activated receptors |
| 01/27/2005 | US20050020670 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran |
| 01/27/2005 | US20050020666 Cardioprotective agents |
| 01/27/2005 | US20050020661 Antidiabetic agents |
| 01/27/2005 | US20050020660 For example, 3-(3-methoxy-1-azabicyclo[2.2.2]oct-3-yl)-1,1-diphenyl-2-propyn-1-ol, 3-[(3R)-3-methoxy-1-azabicyclo [2.2.2]oct-3-yl]-1,1-diphenyl-2-propyn-1-ol; particularly suited for treating urinary incontinence |
| 01/27/2005 | US20050020657 Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 |
| 01/27/2005 | US20050020656 L-histidine, D-histidine, DL-histidine, and/or salts thereof, and optionally cysteine, and/or cystine or salts; fibrosis may be of the kidney, pancreas, lung, vascular vessels, skin, bone marrow, or liver; may be given in foods or beverages |
| 01/27/2005 | US20050020652 For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus |
| 01/27/2005 | US20050020651 Butyric acid derivatives |
| 01/27/2005 | US20050020634 Acat inhibitors; cardiovascular disorders; restenosis; Alzheimer's disease |
| 01/27/2005 | US20050020624 Dihydroindole and tetrahydroquinoline derivatives |
| 01/27/2005 | US20050020621 Prevent reduced blood flow to brain |
| 01/27/2005 | US20050020614 Stabilization plaque in blood vessels; therapy for restenosis in diabetic patients |
| 01/27/2005 | US20050020609 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 01/27/2005 | US20050020606 2,4-Bis (trifluoroethoxy)pyridine compound and drug containing the compound |
| 01/27/2005 | US20050020604 5-HT receptor ligands and uses thereof |
| 01/27/2005 | US20050020584 Benzamide derivatives as antagonists of orexin receptors |
| 01/27/2005 | US20050020583 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2005 | US20050020578 Oxidoreductase enzyme inhibitors such as (R)-1-[4-(2-methyl-4-phenyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-pyrimidin-2-yl-ethanol, used as antidiabetic agents |
| 01/27/2005 | US20050020573 5HT2c receptor modulators |
| 01/27/2005 | US20050020562 Drugs; analgesics; anesthetics; antiarrhythmia agents; antiinflammatory agents ; incontinence; gastrointestinal disorders; neurodegenerative disease |
| 01/27/2005 | US20050020541 Moderate neurotransmitters |
| 01/27/2005 | US20050020540 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050020500 Glycosaminoglycan-polypeptide complex; antiarthritic agents |
| 01/27/2005 | US20050020484 Using protein mixture of lactoferrin and albumin; anticholesterol agents; antilipemic agents; obesity, hypotensive agents, antidiabetic agents |
| 01/27/2005 | US20050020481 Ion channel modulating compounds and uses thereof |
| 01/27/2005 | US20050019908 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 01/27/2005 | US20050019869 Chimeric neuropeptide Y receptors |
| 01/27/2005 | US20050019826 Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof |
| 01/27/2005 | US20050019821 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/27/2005 | US20050019765 Methods for treating disorders of the nervous and reproductive systems |
| 01/27/2005 | US20050019763 Isolated polypeptide of given sequence; expression vectors, host cells, antibodies, agonists, and antagonists; use in diagnosing, treating, or preventing various disorders |
| 01/27/2005 | US20050019395 Formulations of amlodipine maleate |
| 01/27/2005 | US20050019304 Novel human mage-like protein |
| 01/27/2005 | CA2851309A1 Compounds and methods for delivery of prostacyclin analogs |
| 01/27/2005 | CA2736406A1 Compositions comprising diethanolamine salts of trepostinil in the treatment of pulmonary hypertension and other cardiovascular diseases |
| 01/27/2005 | CA2537222A1 Use of nitrite salts for the treatment of cardiovascular conditions |
| 01/27/2005 | CA2532316A1 Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases |
| 01/27/2005 | CA2529790A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 01/27/2005 | CA2525949A1 Transgenic cells expressing proteins involved in fatty acid biosynthesis |
| 01/26/2005 | EP1500698A1 Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| 01/26/2005 | EP1500658A1 Novel thiol derivative, process for producing the same and use thereof |
| 01/26/2005 | EP1500657A1 Substituted pyrazoles as P38 kinase inhibitors |
| 01/26/2005 | EP1500654A1 Benzoxazinone derivatives, the preparation and use thereof as medicaments |
| 01/26/2005 | EP1500648A1 Novel piperidine derivative |
| 01/26/2005 | EP1500643A1 Benzamide derivatives |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500401A1 Drugs for treating vascular diseases |
| 01/26/2005 | EP1500400A1 Drug containing antibody composition |
| 01/26/2005 | EP1500392A1 Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499631A2 Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499619A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof |
| 01/26/2005 | EP1499614A1 Adenosine a3 receptor modulators |
| 01/26/2005 | EP1499610A2 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them |
| 01/26/2005 | EP1499608A1 Substituted imidazole derivatives: gaba a receptor ligands |
| 01/26/2005 | EP1499607A1 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists |
| 01/26/2005 | EP1499605A2 NF-KappaB INHIBITORS |
| 01/26/2005 | EP1499600A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |